Archive for Clinical Trials & Medical Discoveries

Study: New Treatment for Traumatic Brain Injury Shows Promise in Animals

Clinical Trials & Medical Discoveries, PR Newswire, Surveys, Polls and Research
NEW ORLEANS, Feb. 19, 2012 /PRNewswire-USNewswire/ -- A new drug is showing promise in shielding against the harmful effects of traumatic brain injury (TBI) in rats, according to a study that was released today and will be presented at the American Academy of Neurology's 64th Annual...

Argos Therapeutics Announces New Data Demonstrating Prolonged Overall Survival in a Phase 2 Study of its Arcelis™ Immunotherapy AGS-003 in Combination with Sunitinib in Patients with Metastatic Renal Cell Carcinoma (mRCC)

Clinical Trials & Medical Discoveries, PR Newswire, Trade Show
DURHAM, N.C., Feb. 4, 2012 /PRNewswire/ -- Argos Therapeutics Inc. today announced that updated results from an open label Phase 2 study of  its Arcelis™ immunotherapy, AGS-003, in combination with sunitinib in patients with unfavorable risk, metastatic renal...

NHS Makes £200 Non-Drug Hypertension Treatment Device Available on Prescription

Clinical Trials & Medical Discoveries, New Products & Services, PR Newswire
LONDON, February 1, 2012 /PRNewswire/ -- From today, an innovative non-drug, non-invasive treatment for high blood pressure will be made available to all hypertensive patients on NHS prescription. RESPeRATE is an interactive respiratory modulation device clinically-proven to lower blood...

Nuevo tratamiento para el cáncer de mama disponible en Italia

Clinical Trials & Medical Discoveries, New Products & Services, PR Newswire, Women
HATFIELD, Reino Unido, January 26, 2012 /PRNewswire/ -- Halaven® (eribulina) aumenta la esperanza de vida de las mujeres con cáncer de mama localmente avanzado o metastásico Halaven® (eribulina), un nuevo tratamiento para pacientes con cáncer de mama...

Neue behandlungsoption bei brustkrebs ab sofort in Italien verfügbar

Clinical Trials & Medical Discoveries, New Products & Services, PR Newswire, Women
HATFIELD, England, January 26, 2012 /PRNewswire/ -- Halaven® (eribulin) erhöht die Lebenserwartung von  Frauen mit lokal fortgeschrittenem oder metastasierendem Brustkrebs Halaven® (eribulin), eine neue Behandlungsoption für Patienten mit lokal...

Cancer du sein : nouveau traitement disponible en Italie

Clinical Trials & Medical Discoveries, New Products & Services, PR Newswire, Women
HATFIELD, Royaume-Uni, January 26, 2012 /PRNewswire/ -- Halaven® (éribuline) prolonge l'espérance de vie des femmes atteintes du cancer du sein localement évolué ou métastatique L'Halaven® (éribuline), un nouveau traitement destiné aux...